Data-driven identification of endophenotypes of Alzheimer's disease progression: implications for clinical trials and therapeutic interventions.
Nophar GeifmanRichard E KennedyLon S SchneiderIain BuchanRoberta Diaz BrintonPublished in: Alzheimer's research & therapy (2018)
Our results, 'learned' from clinical data, indicate the existence of at least three subgroups of Alzheimer's patients, each demonstrating a different trajectory of disease progression. This hypothesis-generating approach has detected distinct AD subgroups that may prove to be discrete endophenotypes linked to specific aetiologies. These findings could enable stratification within a clinical trial or study context, which may help identify new targets for intervention and guide better care.
Keyphrases
- clinical trial
- end stage renal disease
- healthcare
- ejection fraction
- randomized controlled trial
- cognitive decline
- chronic kidney disease
- newly diagnosed
- palliative care
- phase ii
- prognostic factors
- peritoneal dialysis
- physical activity
- double blind
- study protocol
- pain management
- affordable care act
- placebo controlled
- bioinformatics analysis